Carasent (Q3 Review) - In good shape for exciting 2026

Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives that have just entered or soon will enter the commercial phase, paving the way for continued ARR growth.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/